The Niche

FDA puts plan for a neural stem cell trial on hold

The FDA has ordered a halt to NeuralStem’s plans for a neural stem cell trial in Lou Gehrig’s disease (amyotrophic lateral sclerosis). (See the company’s press release as well as a link to its December announcement that it had filed an IND) NeuralStem says that the FDA’s concerns and recommendations can be readily addressed. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE